Shattuck Labs Inc
NASDAQ:STTK
Shattuck Labs Inc
NASDAQ:STTK
Price:
6.42
USD
2.72%
Market Closed
Market Cap:
$459.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Shattuck Labs Inc
NASDAQ:STTK
|
US |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
US |
|
Atresmedia Corporacion de Medios de Comunicacion SA
MAD:A3M
|
ES |
|
Crescent Point Energy Corp
TSX:CPG
|
CA |
|
Capitaland Investment Ltd
OTC:CLILF
|
SG |
|
Shaver Shop Group Ltd
ASX:SSG
|
AU |
|
TTEC Holdings Inc
NASDAQ:TTEC
|
US |
|
K
|
KPM Tech Co Ltd
KOSDAQ:042040
|
KR |
|
A
|
Adamant Holding Inc
CNSX:ADMT
|
CA |
|
K
|
Kancera AB
F:3EE0
|
SE |
|
C
|
ClouDr Group Ltd
HKEX:9955
|
CN |
|
S
|
SMC Electric Ltd
HKEX:2381
|
HK |
|
L
|
L'Oreal SA
F:LOR
|
FR |
|
C
|
Ceres Power Holdings PLC
F:CFJ
|
UK |
|
Openpay Group Ltd
ASX:OPY
|
AU |
|
IIFL Securities Ltd
NSE:IIFLSEC
|
IN |
Multiples-Based Value
The Multiples-Based Value of one
STTK
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 6.42 USD,
Shattuck Labs Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
STTK Multiples-Based Value
LOCKED
Multiples Across Competitors
STTK Competitors Multiples
Shattuck Labs Inc Competitors
Shattuck Labs Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Shattuck Labs Inc
NASDAQ:STTK
|
459.4m USD | 459.4 | -9.4 | -8 | -7.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
